Access cutting-edge clinical high risk for psychosis (chr) treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this New York location
Preparing your pre-screening questions…
Access clinical high risk for psychosis (chr) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related clinical high risk for psychosis (chr) treatment provided free
Check if you qualify for this clinical high risk for psychosis (chr) clinical trial in New York, NY
No-Cost Study Care
Local to New York
Convenient for NY residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This study aims to evaluate the feasibility and effectiveness of telehealth interventions for individuals at clinical high risk for psychosis (CHR). Psychosis typically emerges during late adolescence or early adulthood, significantly impacting long-term functioning. While CHR programs have the potential to reduce illness severity, individuals often face barriers such as stigma and limited access to services. Telehealth interventions could address these barriers and improve treatment accessibility and engagement. The study will focus on Group and Family-Based Cognitive Behavioral Therapy, Family-Based CBT, and individual CBT, adapted for telehealth delivery (GF-CBT-TH, F-CBT-TH, and I-CBT-TH). Participants aged 14-25 who meet CHR criteria will be randomly assigned to one of these interventions. Feasibility will be measured by recruitment rate, attendance, and retention. The study will assess the impact of the interventions on cognitive biases, social connectedness, family emotional climate, and proficiency in CBT skills. The three intervention groups will be compared in terms of psychosocial functioning, symptom severity, rates of remission from CHR, and rates of transition to psychosis. Additionally, factors like patient treatment preference, family emotional climate, and sociodemographic factors will be explored as potential moderators of treatment outcomes. Qualitative interviews will be conducted with participants and clinicians to inform dissemination efforts.
Sponsor: Icahn School of Medicine at Mount Sinai
Yes, this clinical trial (NCT05968560) has an active research site in New York, NY that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for clinical high risk for psychosis (chr) treatment options in New York, NY, this clinical trial (NCT05968560) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced clinical high risk for psychosis (chr) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all clinical high risk for psychosis (chr) clinical trials near you to find additional studies recruiting in your area.
See all schizophrenia clinical trials recruiting in New York — not just this study.
Browse Schizophrenia Trials in New York →